Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Non-Current Assets (2020 - 2024)

Historic Non-Current Assets for Universe Pharmaceuticals (UPC) over the last 6 years, with Q3 2025 value amounting to $15.7 billion.

  • Universe Pharmaceuticals' Non-Current Assets fell 377.46% to $15.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 billion, marking a year-over-year decrease of 377.46%. This contributed to the annual value of $15.7 billion for FY2025, which is 377.46% down from last year.
  • According to the latest figures from Q3 2025, Universe Pharmaceuticals' Non-Current Assets is $15.7 billion, which was down 377.46% from $16.3 billion recorded in Q3 2024.
  • In the past 5 years, Universe Pharmaceuticals' Non-Current Assets ranged from a high of $16.3 billion in Q3 2024 and a low of $15.9 million during Q1 2024
  • Moreover, its 5-year median value for Non-Current Assets was $18.8 million (2021), whereas its average is $4.0 billion.
  • As far as peak fluctuations go, Universe Pharmaceuticals' Non-Current Assets plummeted by 9999.96% in 2021, and later skyrocketed by 9905424.56% in 2024.
  • Universe Pharmaceuticals' Non-Current Assets (Quarter) stood at $19.7 million in 2021, then fell by 8.29% to $18.0 million in 2022, then decreased by 8.76% to $16.5 million in 2023, then soared by 99054.25% to $16.3 billion in 2024, then fell by 3.77% to $15.7 billion in 2025.
  • Its last three reported values are $15.7 billion in Q3 2025, $16.3 billion for Q3 2024, and $15.9 million during Q1 2024.